Key result
BNP and NT-proBNP serve as valuable biomarkers for aging, HF diagnosis, and predicting adverse events.
Why the study?
To examine the prospects for the practical use of natriuretic peptide levels as biomarkers of aging and morbidity.
BNP and NT-proBNP levels have potential as biomarkers for biological aging and prognostic indicators for all-cause mortality, extending beyond their established role in heart failure diagnosis.
Answers are grounded in this paper and cite their sources.
May extend natriuretic peptides to aging biomarkers; leaves open prospective validation before clinical adoption.
This brief review examines the prospects for the practical use of natriuretic peptide levels as biomarkers of aging and morbidity. A comparison of discrete and continuous methods for assessing these indicators is made. Their place in the comprehensive diagnostics of acute and chronic heart failure with preserved and reduced ejection fraction and with atrial fibrillation is determined. The prognostic value of natriuretic peptide levels as risk factors for adverse events and death in patients with chronic pathology and in healthy individuals is also discussed.
No takes yet. Share an insight, caveat, or question.
Dzeranova et al. (2024) conducted a review in Heart failure, aging, atrial fibrillation. Blood Natriuretic Peptide Levels (BNP, NT-proBNP) was evaluated. Blood natriuretic peptide levels (BNP and NT-proBNP) serve as valuable biomarkers for aging and morbidity, particularly in diagnosing heart failure and predicting adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: